TrialMolecular cancer therapeutics2025

Pretargeted Anti-CD20 Radioimmunotherapy with scFv Fusion Protein Safely Combines with BEAM and ASCT in Patients with High-risk B-cell Lymphomas.

Johnnie J Orozco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.